This trial is designed to see if briefly holding certain medications around the time of getting a booster COVID-19 vaccine dose improves the response to the vaccine, with safety concerns for the effects of the autoimmune disease in mind.
1 Primary · 2 Secondary · Reporting Duration: 6 months following COVID-19 vaccine booster
1000 Total Participants · 9 Treatment Groups
Primary Treatment: Upadacitinib · No Placebo Group · Phase 4
Age 18 - 85 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: